When chip giant Nvidia (NVDA) shows interest in any company, analysts and investors take note. According to Nvidia’s most recent 13F filing, the company now owns 833,325 shares of AI biotech company Generate Biomedicines (GENB), with the position valued at around $10.4 million.
This investment might be small for Nvidia with its massive balance sheet and multi-billion-dollar AI infrastructure bets. However, for a small clinical-stage biotech company, Nvidia’s trust and investment could carry a lot of significance. GENB stock went public in late February 2026 and has already earned a “Strong Buy” consensus rating on Wall Street, despite rising just 8% from its opening price of $12.01 on March 2.